Abstract

Four and a half LIM protein 1 (FHL1/SLIM1) is highly expressed in skeletal and cardiac muscle; however, the function of FHL1 remains unknown. Yeast two-hybrid screening identified slow type skeletal myosin-binding protein C as an FHL1 binding partner. Myosin-binding protein C is the major myosin-associated protein in striated muscle that enhances the lateral association and stabilization of myosin thick filaments and regulates actomyosin interactions. The interaction between FHL1 and myosin-binding protein C was confirmed using co-immunoprecipitation of recombinant and endogenous proteins. Recombinant FHL2 and FHL3 also bound myosin-binding protein C. FHL1 impaired co-sedimentation of myosin-binding protein C with reconstituted myosin filaments, suggesting FHL1 may compete with myosin for binding to myosin-binding protein C. In intact skeletal muscle and isolated myofibrils, FHL1 localized to the I-band, M-line, and sarcolemma, co-localizing with myosin-binding protein C at the sarcolemma in intact skeletal muscle. Furthermore, in isolated myofibrils FHL1 staining at the M-line appeared to extend partially into the C-zone of the A-band, where it co-localized with myosin-binding protein C. Overexpression of FHL1 in differentiating C2C12 cells induced "sac-like" myotube formation (myosac), associated with impaired Z-line and myosin thick filament assembly. This phenotype was rescued by co-expression of myosin-binding protein C. FHL1 knockdown using RNAi resulted in impaired myosin thick filament formation associated with reduced incorporation of myosin-binding protein C into the sarcomere. This study identified FHL1 as a novel regulator of myosin-binding protein C activity and indicates a role for FHL1 in sarcomere assembly.

Highlights

  • Complete LIM domains, preceded by an N-terminal half LIM domain [10]

  • We have reported previously that in myoblasts FHL3 binds skeletal ␣-actin and inhibits ␣-actinin-mediated actin cross-linking, suggesting that FHL proteins may play an important role in regulating cytoskeletal dynamics [21]

  • The C10 domain that bound FHL1 in Y2H is highly homologous in all three myosin-binding protein C (MyBP-C) isoforms and binds the rod (LMM) region of myosin (Fig. 1, B and C) [22, 28, 29]

Read more

Summary

Polypeptide expressed

FHL1 full-length (amino acids 1–280) FHL1 LIM domains 1/2, 1 and 2) (amino acids 1–157). The role of MyBP-C in striated muscle is contentious; MyBP-C may be required for the formation and stabilization of normal myosin thick filaments and for the regulation of myosin cross-bridge kinetics [22, 25]. Expression of MyBP-C lacking the C10 domain, in skeletal myotubes and cardiomyocytes, potently inhibits sarcomere formation [37, 38]. Cardiac MyBP-C(ϩ) exhibits reduced binding affinity for myosin and titin in vitro and disrupts sarcomere formation when expressed in cardiomyocytes. These studies highlight the importance of the C10 myosin-binding domain to MyBP-C activity. In an in vitro assay FHL1 impaired the co-sedimentation of MyBP-C with myosin filaments, suggesting FHL1 and myosin compete for binding to domain C10 of MyBP-C. Overexpression of FHL1 and RNAi-mediated knockdown of FHL1 in differentiating C2C12 cells indicate FHL1 is a novel regulator of MyBP-C activity and thereby sarcomeric assembly

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call